D.E. Shaw & Co Portfolio holdings
D. E. Shaw & Co., L.P., founded in 1988 by David E. Shaw, a former Columbia University computer science professor, is a New York City-based global investment management firm renowned for pioneering quantitative investing, managing over $70 billion in assets as of late 2024. Starting with $28 million from Paloma Partners and private investors, the firm employs sophisticated mathematical models and proprietary algorithms—initially developed by a team of scientists and programmers—to exploit market anomalies across public and private markets, including equities, fixed income, and alternatives. Headquartered above a Greenwich Village bookstore in its early days, it now boasts over 2,500 employees across offices in North America, Europe, and Asia, led by a seven-member Executive Committee since Shaw stepped back in 2001 to focus on D. E. Shaw Research. Despite setbacks like the 1998 Russia debt crisis and the 2008 financial downturn, the firm has maintained a reputation for analytical rigor, risk management, and innovation, balancing its computational roots with discretionary strategies.
Top Buys
| 1 |
Apple
AAPL
|
$773M |
| 2 |
Visa
V
|
$674M |
| 3 |
HES
Hess
HES
|
$541M |
| 4 |
Mastercard
MA
|
$448M |
| 5 |
Oracle
ORCL
|
$419M |
Top Sells
| 1 |
NVIDIA
NVDA
|
$1.29B |
| 2 |
Advanced Micro Devices
AMD
|
$979M |
| 3 |
Citigroup
C
|
$477M |
| 4 |
Exxon Mobil
XOM
|
$434M |
| 5 |
Booking.com
BKNG
|
$355M |
Sector Composition
| 1 | Technology | 27.95% |
| 2 | Consumer Discretionary | 14.18% |
| 3 | Financials | 9.99% |
| 4 | Healthcare | 9.55% |
| 5 | Communication Services | 6.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
326
Kinsale Capital Group
KNSL
$10.5B
| $37.7M | 0.03% |
71,892
+3,356
| +5% | +$1.76M |
|
|
CNH
327
CNH Industrial
CNH
$14.4B
| $37.7M | 0.03% |
2,907,341
+447,923
| +18% | +$5.81M |
|
328
Paychex
PAYX
$48.7B
| $37.6M | 0.03% |
306,046
+25,765
| +9% | +$3.16M |
|
329
Azenta
AZTA
$1.35B
| $37.5M | 0.03% |
621,866
-107,319
| -15% | -$6.47M |
|
330
Goldman Sachs
GS
$225B
| $37.4M | 0.03% |
89,471
-248,995
| -74% | -$104M |
|
331
BellRing Brands
BRBR
$4.51B
| $37M | 0.03% |
626,779
-280,291
| -31% | -$16.5M |
|
332
BioMarin Pharmaceuticals
BMRN
$10.8B
| $36.9M | 0.03% |
422,298
+229,846
| +119% | +$20.1M |
|
333
XPeng
XPEV
$19.6B
| $36.3M | 0.03% |
4,725,835
-464,627
| -9% | -$3.57M |
|
334
Chemed
CHE
$6.76B
| $36.2M | 0.03% |
56,464
+4,594
| +9% | +$2.95M |
|
335
Axalta
AXTA
$7.01B
| $36.1M | 0.03% |
1,049,258
+75,238
| +8% | +$2.59M |
|
336
Altice USA
ATUS
$1.05B
| $35.9M | 0.03% |
13,769,174
+3,441,816
| +33% | +$8.98M |
|
|
BPMC
337
DELISTED
Blueprint Medicines
BPMC
| $35.7M | 0.03% |
376,177
+26,860
| +8% | +$2.55M |
|
338
PTC Therapeutics
PTCT
$4.52B
| $35.7M | 0.03% |
1,225,748
-121,219
| -9% | -$3.53M |
|
339
ADMA Biologics
ADMA
$3.92B
| $35.5M | 0.03% |
5,381,718
-1,131,835
| -17% | -$7.47M |
|
340
Loews
L
$19.9B
| $35.3M | 0.03% |
450,522
-9,447
| -2% | -$740K |
|
341
Corteva
CTVA
$49.5B
| $35.1M | 0.03% |
608,809
-1,308,981
| -68% | -$75.5M |
|
342
Liberty Live Group Series A
LLYVA
$8.95B
| $34.9M | 0.03% |
825,191
+77,105
| +10% | +$3.27M |
|
343
Iovance Biotherapeutics
IOVA
$861M
| $34.9M | 0.03% |
2,352,166
+2,137,032
| +993% | +$31.7M |
|
344
Boeing
BA
$175B
| $34.8M | 0.03% |
180,182
-79,486
| -31% | -$15.3M |
|
345
Vita Coco
COCO
$2.18B
| $34.7M | 0.03% |
1,421,499
-149,033
| -9% | -$3.64M |
|
346
Harley-Davidson
HOG
$3.77B
| $34.6M | 0.03% |
790,254
-735,326
| -48% | -$32.2M |
|
|
RBCP
347
DELISTED
RBC Bearings Incorporated 5.00% Series A Mandatory Convertible Preferred Stock
RBCP
| $34.4M | 0.03% |
280,000
| – | – |
|
348
TTM Technologies
TTMI
$4.86B
| $34.2M | 0.03% |
2,188,382
+225,643
| +11% | +$3.53M |
|
349
Spotify
SPOT
$148B
| $34.1M | 0.03% |
129,399
-219,661
| -63% | -$58M |
|
350
Thermo Fisher Scientific
TMO
$184B
| $33.5M | 0.03% |
57,676
-44,821
| -44% | -$26.1M |
|